Adverse Childhood and Lifespan Stressors Take a Toll on MS Disease Severity
Andrew Wilner, MD, FACP, FAAN
Carri Polick, PhD, RN
MS in Black and Hispanic Patients: Examining Prevalence and Disease Characteristics
Jennifer Caudle, DO
Mitzi Joi Williams, MD
Mind Matters: Psychiatric Comorbidity in the Prodromal Phase of MS
Charles Turck, PharmD, BCPS, BCCCP
Anibal Chertcoff, MD
Examining Emerging Gut Microbiota Biomarkers for MS
MS in Children: Exploring Biomarker Research Advancements
Ahmed Abdelhak, MD
New Consensus for Smoldering Disease in MS
Discussing Disparities in MS Care for Underrepresented Populations
Tirisham V. Gyang, MD
Gopika Govindan Kutty, MD
An Overview of MS Biomarkers
Discussing the Latest in MS Treatment and Disease-Modifying Therapies
Jay Avasarala, MD, PhD
Highlights from the 2023 Psych Congress
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Craig Chepke, MD, FAPA
A New Hope for Patients with MS – The First FDA-Approved Biosimilar
Diagnosing Suspected MS: A Review of the Updated Guidelines
Eoin Flanagan, MB, BCh
The Hidden Struggles of Tardive Dyskinesia: Improving Patient Care
Locked Up in My Own Mind: Challenges in the Criminal Justice System
Clarity for Schizophrenia: The Latest in Drug Treatment
New Drug Approved for PPD: Solving an Unmet Need
Loading...
We're glad to see you're enjoying Global Neurology Academy… but how about a more personalized experience?
Press cancel to remain on Global Neurology Academy. Press the link below or the continue button to keep going.